Also the combination of Adavosertib with the highly specific PARP catalytic inhibitor and potent trapper of PARP1 Talazoparib did not enhance therapeutic efficacy in HNSCC-derived cell lines (Fig. S3a,b). The gene discussed is PARP1; the disease is head and neck squamous cell carcinoma.